Parkman Healthcare Partners LLC
Position in AMLX — Amylyx Pharmaceuticals, Inc.
CIK 1777015
STAMFORD, CT
Position in AMLX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$8,638,266
+$4,026,606 QoQ
Shares Held
621,458
+62.8% QoQ
Ownership
0.559%
of shares outstanding
% of Portfolio
0.90%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in AMLX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Parkman Healthcare Partners LLC holds $90,125,176 across 8 Drug Manufacturers - Specialty & Generic names. AMLX ranks #6 (9.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ANIP |
Ani Pharmaceuticals Inc
|
280,575 | $21,576,217 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,708,099 | $16,261,102 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
99,069 | $13,051,350 | |
| 4 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
259,184 | $12,479,709 | |
| 5 | XERS |
Xeris Biopharma Holdings, Inc.
|
1,721,264 | $9,983,331 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
This page
|
621,458 | $8,638,266 | |
| 7 | SUPN |
Supernus Pharmaceuticals, Inc.
|
85,062 | $4,396,854 | |
| 8 | AMRX |
Amneal Pharmaceuticals, Inc.
|
300,752 | $3,738,347 |
All Filings in AMLX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,638,266 | 621,458 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $4,611,660 | 381,760 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,870,974 | 579,174 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $4,166,500 | 650,000 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||